BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36736783)

  • 1. Clinical Benefit of Low-Dose Antithymocyte Globulin-Thymoglobulin as Graft-versus-Host Disease Prophylaxis in Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Identical Donors.
    Takeuchi Y; Miyao K; Negishi S; Ohara F; Motegi K; Wakabayashi H; Yokota H; Kuwano S; Sawa H; Inagaki Y; Sawa M
    Transplant Cell Ther; 2023 May; 29(5):325.e1-325.e10. PubMed ID: 36736783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.
    Miyao K; Kuwatsuka Y; Murata M; Nagafuji K; Teshima T; Takeuchi Y; Shiratori S; Najima Y; Uchida N; Tanaka M; Sawa M; Ota S; Fukuda T; Ozawa Y; Kako S; Kawakita T; Ara T; Tanaka J; Kanda Y; Atsuta Y; Kanda J; Terakura S;
    Transplant Cell Ther; 2022 Mar; 28(3):153.e1-153.e11. PubMed ID: 34954151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
    Nakaya Y; Koh H; Konuma T; Shimomura Y; Ishiyama K; Itonaga H; Hino M; Doki N; Nishida T; Ohigashi H; Matsuoka KI; Kanda Y; Maruyama Y; Sawa M; Eto T; Hiramoto N; Fukuda T; Atsuta Y; Nakamae H
    Transplant Cell Ther; 2024 Mar; 30(3):316.e1-316.e12. PubMed ID: 38108263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study.
    Huang W; Zhao X; Tian Y; Cao T; Li Y; Liu Z; Jing Y; Wang S; Gao C; Yu L
    Med Oncol; 2015 Feb; 32(2):465. PubMed ID: 25588925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors.
    Wang N; Wang H; Fang S; Du J; Huang S; Li F; Jin X; Jia M; Xu L; Dou L; Liu D
    Transplant Cell Ther; 2022 Nov; 28(11):769.e1-769.e9. PubMed ID: 35973670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors.
    Shiratori S; Sugita J; Fuji S; Aoki J; Sawa M; Ozawa Y; Hashimoto D; Matsuoka KI; Imada K; Doki N; Ashida T; Ueda Y; Tanaka M; Sawayama Y; Ichinohe T; Terakura S; Morishima S; Atsuta Y; Fukuda T; Teshima T
    Bone Marrow Transplant; 2021 Sep; 56(9):2231-2240. PubMed ID: 33963304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antithymocyte globulin for GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation].
    Shiratori S
    Rinsho Ketsueki; 2021; 62(8):1265-1274. PubMed ID: 34497215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
    Salas MQ; Alfaro-Moya T; Atenafu EG; Datt Law A; Lam W; Pasic I; Novitzky-Basso I; Santos Carreira A; Chen C; Michelis FV; Gerbitz A; Howard Lipton J; Kim DDH; Kumar R; Mattsson J; Viswabandya A
    Transplant Cell Ther; 2024 May; 30(5):536.e1-536.e13. PubMed ID: 38281592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
    Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
    Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
    Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria.
    Knaus HA; Rottner T; Baumann CK; Cserna J; Mitterbauer M; Schulenburg A; Rabitsch W; Wohlfarth P
    Transplant Cell Ther; 2022 May; 28(5):260.e1-260.e9. PubMed ID: 35217212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of low-dose ATG for GVHD prophylaxis in patients undergoing PBSCT aged over forty years old].
    Liang C; Jiang EL; Yao JF; Ma QL; Zhai WH; Pang AM; Huang Y; Wei JL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):292-298. PubMed ID: 29779324
    [No Abstract]   [Full Text] [Related]  

  • 15. Graft-Versus-Host Disease Prophylaxis Using Low-Dose Antithymocyte Globulin in Peripheral Blood Stem Cell Transplantation-A Matched-Pair Analysis.
    Shiratori S; Kurata M; Sugita J; Ota S; Kasahara S; Ishikawa J; Imada K; Onishi Y; Ishiyama K; Ashida T; Kanda Y; Ichinohe T; Fukuda T; Atsuta Y; Teshima T
    Transplant Cell Ther; 2021 Dec; 27(12):995.e1-995.e6. PubMed ID: 34500126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft
    Li T; He Q; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Ding X; Tong Y; Wan L; Song X
    Cell Transplant; 2022; 31():9636897221139103. PubMed ID: 36433646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial.
    Zu Y; Li Z; Gui R; Liu Y; Zhang Y; Yu F; Zhao H; Fu Y; Zhan X; Wang Z; Xing P; Wang X; Wang H; Zhou J; Song Y
    Bone Marrow Transplant; 2022 Oct; 57(10):1573-1580. PubMed ID: 35840747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.
    Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A
    Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies.
    Dou L; Wang L; Li X; Liu Y; Li F; Wang L; Gao X; Huang W; Wang S; Gao C; Yu L; Liu D
    Medicine (Baltimore); 2021 Feb; 100(8):e24725. PubMed ID: 33663084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.